The popularity of GLP-1 weight-loss drugs, namely Wegovy and Ozempic, is diminishing as discussions around their side effects and risks gain traction among healthcare providers. Despite studies indicating their effectiveness for obesity management and potential heart health benefits, challenges related to high costs and inconsistent insurance coverage hinder accessibility. Medical professionals express concern over patients’ unrealistic expectations regarding the medications. Notably, many patients cease usage within two years, indicating that while these treatments can be life-altering, they are not a universal or permanent solution.
The luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients about side effects and risks.
Many patients have begun taking the drugs with unrealistic expectations and little guidance, leading to high dropout rates within two years.
Collection
[
|
...
]